Regeneron Pharmaceuticals (REGN) Enterprise Value (2009 - 2026)

Regeneron Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$8.0 billion for Q2 2026.

• In Q2 2026, Enterprise Value fell 7.03% year-over-year to -$8.0 billion; the TTM figure through Jun 2026 stood at -$8.0 billion (down 7.03% YoY), while the FY2025 annual figure was -$8.6 billion, up 4.52% from the prior year.
• Enterprise Value for Q2 2026 stood at -$8.0 billion, up from -$8.8 billion in the prior quarter.
• The five-year high for Enterprise Value was -$7.0 billion in Q3 2022, with the low at -$10.8 billion in Q4 2023.
• The 5-year median for Enterprise Value is -$8.7 billion (2025), against an average of -$8.7 billion.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value tumbled 101.23% in 2022, then gained 23.85% in 2025.
• Regeneron Pharmaceuticals' Enterprise Value stood at -$7.7 billion in 2022, then plunged by 40.07% to -$10.8 billion in 2023, then climbed by 16.9% to -$9.0 billion in 2024, then advanced by 4.52% to -$8.6 billion in 2025, then advanced by 7.1% to -$8.0 billion in 2026.
• Business Quant data shows REGN's Enterprise Value at -$8.0 billion in Q2 2026, -$8.8 billion in Q1 2026, and -$8.6 billion in Q4 2025.